BrightPath Biotherapeutics Co.Ltd. (4594) AI Stock Analysis

• Market Cap: ¥7.57B
• Dividend Yield: N/A
• Average Volume (3M): 3.44M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: 1254.76%
• EPS Growth: 33.94%
• Country: JP
• Employees: 42
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.59
• Shares Outstanding: 111,391,300
• 10 Day Avg. Volume: 1,839,730
• 30 Day Avg. Volume: 3,435,483
• PEG Ratio: 0.14
• Price to Book (P/B): 3.88
• Price to Sales (P/S): 3165.29
• P/FCF Ratio: -2.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥77.00
• Price Target Upside: 13.24% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ¥67.00 ▼(-1.47% Downside)

BrightPath Biotherapeutics has a challenging financial position with ongoing losses and negative cash flow, which are the most significant factors impacting the score. Technical analysis suggests potential for a short-term rebound, but the overall trend remains bearish. The valuation is unattractive due to negative earnings and lack of dividends.

BrightPath Biotherapeutics Co.Ltd. Business Overview & Revenue Model

Company Description

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.

How the Company Makes Money

BrightPath Biotherapeutics generates revenue primarily through the development, licensing, and commercialization of its biotherapeutic products. The company earns money by advancing its drug candidates through clinical trials and, upon successful approval, commercializing these therapies in collaboration with healthcare providers or pharmaceutical companies. Additionally, BrightPath engages in strategic partnerships and collaborations with other biotech and pharmaceutical firms, which may include licensing agreements, research and development collaborations, and milestone payments. These partnerships not only provide funding but also enhance the company's capabilities in bringing its therapies to market. Revenue is also derived from potential upfront payments, royalties, and sales of approved therapies, contributing significantly to the company's earnings.

BrightPath Biotherapeutics Co.Ltd. Financial Statement Overview

Summary

BrightPath Biotherapeutics faces significant financial challenges with consistent negative EBIT, EBITDA, and net income figures. Despite a strong equity base and low leverage, the company struggles with profitability and cash flow generation. The biotech industry's need for substantial R&D investment may contribute to these financial difficulties.

Income Statement

BrightPath Biotherapeutics has been experiencing significant challenges with consistent negative EBIT, EBITDA, and net income figures over the years. Despite a sharp increase in total revenue from 2024 to 2025, the company is still operating at a loss. Gross profit margin improved in 2025, but the net profit margin remains deeply negative, indicating ongoing operational inefficiencies and high costs relative to revenue.

Balance Sheet

The company's equity ratio is strong, indicating a robust equity base relative to total assets. However, the company has been consistently operating with net losses, which could affect equity over time. The debt-to-equity ratio is low, reflecting minimal leverage and a conservative capital structure, which is a positive aspect. However, persistent losses could threaten the long-term sustainability of this structure.

Cash Flow

BrightPath Biotherapeutics has a negative free cash flow, which is concerning for its liquidity and operational funding. Operating cash flow is also negative, indicating that the company is not generating sufficient cash from its core operations to cover expenses. The reliance on financing cash flow to bridge cash deficits suggests potential sustainability issues if the trend persists.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	118.00K	1.13M	72.00K	5.28M	15.41M	2.50M
Gross Profit	-511.00K	1.10M	-341.00K	3.38M	12.09M	1.36M
EBITDA	-1.20B	-1.15B	-1.17B	-1.47B	-1.45B	-1.65B
Net Income	-1.21B	-1.15B	-1.17B	-1.49B	-1.48B	-1.72B
Balance Sheet
Total Assets	1.43B	1.12B	1.23B	1.70B	2.77B	3.75B
Cash, Cash Equivalents and Short-Term Investments	1.30B	810.47M	1.06B	1.53B	2.31B	3.27B
Total Debt	500.00M	25.00M	112.50M	0.00	87.50M	0.00
Total Liabilities	655.82M	195.62M	251.27M	133.91M	239.73M	211.79M
Stockholders Equity	772.75M	924.99M	978.99M	1.57B	2.53B	3.54B
Cash Flow
Free Cash Flow	8.98M	-1.25B	-1.16B	-1.21B	-1.53B	-1.81B
Operating Cash Flow	8.98M	-1.25B	-1.16B	-1.20B	-1.51B	-1.77B
Investing Cash Flow	0.00	-1.37M	-7.65M	-1.76M	-17.57M	-36.21M
Financing Cash Flow	0.00	1.00B	690.96M	432.10M	569.23M	2.05B

BrightPath Biotherapeutics Co.Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 68.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4594, the sentiment is Positive. The current price of 68 is below the 20-day moving average (MA) of 71.05, below the 50-day MA of 75.82, and above the 200-day MA of 52.67, indicating a neutral trend. The MACD of -2.95 indicates Positive momentum. The RSI at 43.83 is Neutral, neither overbought nor oversold. The STOCH value of 19.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4594.

BrightPath Biotherapeutics Co.Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	69 Neutral	¥4.33B	16.78	―	―	9.47%	14.00%
2342	56 Neutral	¥3.51B	―	―	1.84%	5.00%	-458.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4594	47 Neutral	¥7.57B	―	―	―	1254.76%	33.94%
4881	38 Underperform	¥4.26B	―	―	―	965.85%	-42.78%
4591	37 Underperform	¥4.93B	―	―	―	-59.53%	11.70%
4598	28 Underperform	¥6.09B	―	―	―	―	20.41%